Chemistry:Cadefrecitinib

From HandWiki

Cadefrecitinib is an investigational new drug that is being developed by Lakefront Biotherapeutics for the treatment of dermatomyositis and systemic lupus erythematosus. It is a TYK2 kinase inhibitor.[1][2][3]

References

  1. ↑ "Cadefrecitinib - Lakefront Biotherapeutics". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800056041. 
  2. ↑ "Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases". Journal of Medicinal Chemistry 67 (11): 8545–8568. June 2024. doi:10.1021/acs.jmedchem.4c00769. PMID 38805213. 
  3. ↑ "Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis". Biomolecules & Therapeutics (Seoul) 34 (3): 519–529. May 2026. doi:10.4062/biomolther.2026.019. PMID 42059024. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Cadefrecitinib&oldid=4582907"